drugset / Trial / NCT04003376

Efficacy of Fractional CO2 Laser as a Mono- or Adjuvant Therapy for Alopecia Areata

NCT04003376

Phase 4 Unknown 40 enrolled Assiut University
RandomizedParallel-groupOpen-labelTreatment

Summary

Alopecia areata is a non-scarring hair loss disorder that affects both sexes equally. Incidence of the disease varies for different populations and in different studies, with global incidence ranging from 0.57% to 3.8%. Etiology of alopecia areata is not completely understood, and the majority of evidence suggests that genetically predisposed individuals, when exposed to an unknown trigger, develop a predominantly autoimmune reaction, leading to acute hair loss. Environmental triggers, including viral or bacterial infections, along with autoimmune disorders, seem to play a major role in the development of alopecia areata.

Timeline

Start
2019-07-26
Primary completion
2021-07-01
Completion
2022-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Platelet Rich Plasma Other / unclassified Topical
Subject Triamcinolone Acetonide Other / unclassified 10 mg/ml Topical
Subject Vitamin D Other / unclassified Topical

Indications